Form 4: Phibro CEO Jack Bendheim Executes Stock Sale Plan

Phibro Animal Health Corporation CEO Jack Bendheim sold 21,520 shares of Class A Common Stock via a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corporation, sold a total of 21,520 shares of Class A Common Stock between April 21 and April 23, 2026.
• The transactions were executed by BFI Co., LLC, an entity over which Mr. Bendheim exercises voting and dispositive power.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 11, 2025.
• Following these transactions, the indirect holdings of BFI Co., LLC were reduced to 95,880 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were conducted through a pre-planned 10b5-1 arrangement, which is a standard and expected practice for corporate insiders.

Positives

• The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the insider's indirect stake in the company.

Risks

• Continued selling by major shareholders or insiders could exert downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the animal health and pharmaceutical sectors, typically used to provide liquidity for executives without signaling a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at companies like Zoetis or Elanco to manage equity holdings while maintaining regulatory compliance.

Related Party Transactions

• The filing discloses that BFI Co., LLC is an entity controlled by CEO Jack Bendheim, and the shares sold were held indirectly through this entity.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the systematic nature of the 10b5-1 plan mitigates concerns regarding sudden divestment.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Phibro Animal Health, PAHC, Insider Trading, Form 4, Jack Bendheim, 10b5-1 Plan